Exchange: NASDAQ·Updated 04:25 PM EDT

About

AnaptysBio, Inc. is a clinical-stage biotechnology company, which engages in delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. The firm’s product pipeline includes Rosnilimab, ANB033, ANB101, Jemperli, and Imsidolimab. It operates through the Biopharma and Royalty Management segments. The Biopharma segment focuses on the development and potential commercialization of innovative immunology therapeutics for autoimmune and inflammatory diseases. The Royalty Management segment manages the financial collaboration for Jemperli with GSK and for imsidolimab with Vanda. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
104

Frequently Asked Questions

What is Market Cap of AnaptysBio Inc?
What is the 52-week high for AnaptysBio Inc?
What is the 52-week low for AnaptysBio Inc?
What is AnaptysBio Inc stock price today?
What was AnaptysBio Inc stock price yesterday?
What is the PE ratio of AnaptysBio Inc?
What is the Price-to-Book ratio of AnaptysBio Inc?
What is the 50-day moving average of AnaptysBio Inc?
How many employees does AnaptysBio Inc have?

Advertisement|Remove ads.